Compare Ishares Msci Brazil ETF (EWZ) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Incyte Corporation — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 2× Ishares Msci Brazil ETF's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Incyte Corporation for 33 Days on average.
| EWZ | INCY | |
|---|---|---|
Market Cap | $11.30B | $22.85B |
Volume | 44,036,597 | 1,927,029 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $129.93 |
52-Week Low | $28.79 | $83.80 |
Typical Hold Time | 50 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.59, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is heavily influenced by Brazil's upcoming October 2026 election, with institutional investors accumulating call options betting on a favorable outcome. Recent news highlights EWZ as a diversifier from U.S. tech exposure, though it faces competition from lower-fee alternatives like FLBR.
The outlook for EWZ hinges on Brazil's election result and commodity trends, offering asymmetric upside if pro-market policies prevail. Key risks include political volatility, U.S. tariff impacts, and currency fluctuations. Wall Street sentiment is cautiously optimistic, with unusual options activity signaling speculative interest in near-term gains.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
